Moderna , Inc. (NASDAQ:MRNA) director Noubar Afeyan, has sold a total of $1,756,176 worth of company stock on July 10, according to a recent SEC filing. The transactions occurred in multiple trades, with prices ranging from $116.01 to $119.95 per share.
The filing detailed that Afeyan offloaded 6,121 shares at an average price of $116.01, 4,279 shares at an average of $117.18, 3,000 shares at an average of $117.83, 1,100 shares at an average of $119.28, and 500 shares at an average of $119.95. After these transactions, Afeyan still holds a substantial number of shares directly and indirectly through various entities.
It was noted in the footnotes of the SEC filing that these sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which was adopted on February 27, 2023, and subsequently amended on November 7, 2023. Such plans allow company insiders to sell a predetermined number of shares at a predetermined time, providing an affirmative defense against accusations of trading on non-public, material information.
The SEC document also mentions the indirect ownership of shares by Afeyan through entities such as Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc. Afeyan is associated with these entities as the sole manager or CEO and sole stockholder, respectively. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Investors and followers of Moderna, Inc. often monitor insider transactions as they provide insights into how top executives perceive the value of the company and its prospects. While such sales are a routine part of executive compensation and financial planning, they are always of interest to the investment community for the signals they may send about the company's future.
In other recent news, Moderna Inc. has been granted a $176 million funding from the U.S. government to advance mRNA-based vaccines targeting pandemic influenza strains. The company's mRNA-1018 vaccine for both H5 and H7 avian influenza viruses is currently in a Phase 1/2 clinical trial, with results expected in 2024. Furthermore, Moderna's mRNA-1283 vaccine has met its primary efficacy endpoint in a Phase 3 trial, and its mRESVIA vaccine has received approval from the U.S. Food and Drug Administration for use in adults aged 60 and over. TD Cowen has maintained a Hold rating on Moderna shares, while Argus has increased its price target on Moderna shares, maintaining a Buy rating. Additionally, the company's combined therapy of mRNA-4157 and KEYTRUDA, in collaboration with Merck, has shown a significant reduction in the risk of recurrence or death in high-risk melanoma patients according to a Phase 2b clinical trial. These are among the recent developments in Moderna's efforts to create effective vaccines and treatments.
InvestingPro Insights
As Moderna, Inc. (NASDAQ:MRNA) navigates the post-pandemic market, the company's financial health and stock performance are under close scrutiny. Recent insider transactions have raised questions about executive confidence in the company's valuation and future trajectory. To provide a clearer picture, we turn to the latest data and insights from InvestingPro.
InvestingPro Tips suggest that Moderna's management has been proactive with share buybacks, signaling a potential confidence in the company's value. Additionally, the company's balance sheet reflects a strong liquidity position, as it holds more cash than debt. With these strategic financial moves, Moderna appears to be fortifying its position despite analysts anticipating a sales decline in the current year.
InvestingPro Data further reveals a complex financial landscape for Moderna. The company's market capitalization stands at $46.71 billion, yet it sports a negative P/E ratio of -7.76, reflecting investor concerns about profitability. Moreover, Moderna's revenue has seen a significant drop of 65.78% over the last twelve months as of Q1 2024, which aligns with the analysts' sales decline projections. Gross profit margins have also suffered, plunging to -70.27% in the same period.
While the stock has experienced volatility, with a 1-month price total return of -17.8%, it has also shown resilience over the longer term, achieving a 3-month price total return of 15.49%. It's worth noting that the stock's price is currently at 71.25% of its 52-week high, with a previous close at $122.82.
For investors seeking a deeper dive into Moderna's financials and stock performance, there are additional InvestingPro Tips available, which can be accessed through the InvestingPro platform. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, and gain access to comprehensive analysis and insights that can help inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.